Cocrystal Pharma - 48 Year Dividend History | COCP
Historical dividend payout and yield for Cocrystal Pharma (COCP) since 1971. The current TTM dividend payout for Cocrystal Pharma (COCP) as of August 22, 2019 is $0.00. The current dividend yield for Cocrystal Pharma as of August 22, 2019 is 0.00%.
||Medical - Biomedical and Genetics
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HepC. Phase 1b studies in HepC infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 6 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 48% of the Company.